FDA
-
-
-
-
-
-
-
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at
-
-
-
-
-
-
-
Zentalis Pharmaceuticals (ZNTL) PT Raised to $6 at Jefferies
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Zentalis Pharmaceuticals (ZNTL)
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Zentalis Pharmaceuticals (ZNTL)
-
-
-
-
-
-
-
Morgan Stanley Downgrades Zentalis Pharmaceuticals (ZNTL) to Equalweight
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
-
327,799 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

